Literature DB >> 29628290

The Immune Landscape of Cancer.

Vésteinn Thorsson1, David L Gibbs2, Scott D Brown3, Denise Wolf4, Dante S Bortone5, Tai-Hsien Ou Yang6, Eduard Porta-Pardo7, Galen F Gao8, Christopher L Plaisier9, James A Eddy10, Elad Ziv11, Aedin C Culhane12, Evan O Paull13, I K Ashok Sivakumar14, Andrew J Gentles15, Raunaq Malhotra16, Farshad Farshidfar17, Antonio Colaprico18, Joel S Parker5, Lisle E Mose5, Nam Sy Vo19, Jianfang Liu20, Yuexin Liu19, Janet Rader21, Varsha Dhankani2, Sheila M Reynolds2, Reanne Bowlby3, Andrea Califano13, Andrew D Cherniack8, Dimitris Anastassiou6, Davide Bedognetti22, Younes Mokrab22, Aaron M Newman23, Arvind Rao19, Ken Chen19, Alexander Krasnitz24, Hai Hu20, Tathiane M Malta25, Houtan Noushmehr25, Chandra Sekhar Pedamallu26, Susan Bullman26, Akinyemi I Ojesina27, Andrew Lamb10, Wanding Zhou28, Hui Shen28, Toni K Choueiri26, John N Weinstein19, Justin Guinney10, Joel Saltz29, Robert A Holt3, Charles S Rabkin30, Alexander J Lazar31, Jonathan S Serody32, Elizabeth G Demicco33, Mary L Disis34, Benjamin G Vincent35, Ilya Shmulevich36.   

Abstract

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant-characterized by differences in macrophage or lymphocyte signatures, Th1:Th2 cell ratio, extent of intratumoral heterogeneity, aneuploidy, extent of neoantigen load, overall cell proliferation, expression of immunomodulatory genes, and prognosis. Specific driver mutations correlated with lower (CTNNB1, NRAS, or IDH1) or higher (BRAF, TP53, or CASP8) leukocyte levels across all cancers. Multiple control modalities of the intracellular and extracellular networks (transcription, microRNAs, copy number, and epigenetic processes) were involved in tumor-immune cell interactions, both across and within immune subtypes. Our immunogenomics pipeline to characterize these heterogeneous tumors and the resulting data are intended to serve as a resource for future targeted studies to further advance the field.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer genomics; immune subtypes; immuno-oncology; immunomodulatory; immunotherapy; integrative network analysis; tumor immunology; tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 29628290      PMCID: PMC5982584          DOI: 10.1016/j.immuni.2018.03.023

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   43.474


  96 in total

1.  Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets.

Authors:  Miao-Xin Li; Juilian M Y Yeung; Stacey S Cherny; Pak C Sham
Journal:  Hum Genet       Date:  2011-12-06       Impact factor: 4.132

2.  Genomic and Functional Approaches to Understanding Cancer Aneuploidy.

Authors:  Alison M Taylor; Juliann Shih; Gavin Ha; Galen F Gao; Xiaoyang Zhang; Ashton C Berger; Steven E Schumacher; Chen Wang; Hai Hu; Jianfang Liu; Alexander J Lazar; Andrew D Cherniack; Rameen Beroukhim; Matthew Meyerson
Journal:  Cancer Cell       Date:  2018-04-02       Impact factor: 31.743

3.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

4.  Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.

Authors:  Justin M Drake; Evan O Paull; Nicholas A Graham; John K Lee; Bryan A Smith; Bjoern Titz; Tanya Stoyanova; Claire M Faltermeier; Vladislav Uzunangelov; Daniel E Carlin; Daniel Teo Fleming; Christopher K Wong; Yulia Newton; Sud Sudha; Ajay A Vashisht; Jiaoti Huang; James A Wohlschlegel; Thomas G Graeber; Owen N Witte; Joshua M Stuart
Journal:  Cell       Date:  2016-08-04       Impact factor: 41.582

5.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.

Authors:  Kyle Ellrott; Matthew H Bailey; Gordon Saksena; Kyle R Covington; Cyriac Kandoth; Chip Stewart; Julian Hess; Singer Ma; Kami E Chiotti; Michael McLellan; Heidi J Sofia; Carolyn Hutter; Gad Getz; David Wheeler; Li Ding
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

6.  A draft network of ligand-receptor-mediated multicellular signalling in human.

Authors:  Jordan A Ramilowski; Tatyana Goldberg; Jayson Harshbarger; Edda Kloppmann; Edda Kloppman; Marina Lizio; Venkata P Satagopam; Masayoshi Itoh; Hideya Kawaji; Piero Carninci; Burkhard Rost; Alistair R R Forrest
Journal:  Nat Commun       Date:  2015-07-22       Impact factor: 14.919

7.  Mutant IDH1 regulates the tumor-associated immune system in gliomas.

Authors:  Nduka M Amankulor; Youngmi Kim; Sonali Arora; Julia Kargl; Frank Szulzewsky; Mark Hanke; Daciana H Margineantu; Aparna Rao; Hamid Bolouri; Jeff Delrow; David Hockenbery; A McGarry Houghton; Eric C Holland
Journal:  Genes Dev       Date:  2017-05-02       Impact factor: 11.361

8.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

9.  WGCNA: an R package for weighted correlation network analysis.

Authors:  Peter Langfelder; Steve Horvath
Journal:  BMC Bioinformatics       Date:  2008-12-29       Impact factor: 3.169

10.  Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.

Authors:  Denise M Wolf; Marc E Lenburg; Christina Yau; Aaron Boudreau; Laura J van 't Veer
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more
  1387 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

3.  Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.

Authors:  Hye-Yeong Kim; Ran Li; Thomas S C Ng; Gabriel Courties; Christopher Blake Rodell; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Matthias Nahrendorf; Ralph Weissleder; Miles A Miller
Journal:  ACS Nano       Date:  2018-12-11       Impact factor: 15.881

Review 4.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

5.  The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.

Authors:  Luka de Vos; Ingela Grünwald; Emma Grace Bawden; Jörn Dietrich; Kathrin Scheckenbach; Constanze Wiek; Romina Zarbl; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  Epigenetics       Date:  2020-04-21       Impact factor: 4.528

6.  Cellular therapy against public neoantigens.

Authors:  Paul M Armistead
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

7.  Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response.

Authors:  Mariko Asaoka; Santosh K Patnaik; Frank Zhang; Takashi Ishikawa; Kazuaki Takabe
Journal:  Breast Cancer Res Treat       Date:  2020-04-13       Impact factor: 4.872

8.  Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment.

Authors:  Anuja Sathe; Susan M Grimes; Billy T Lau; Jiamin Chen; Carlos Suarez; Robert J Huang; George Poultsides; Hanlee P Ji
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

9.  Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

Authors:  Anne Fröhlich; Judith Sirokay; Simon Fietz; Timo J Vogt; Jörn Dietrich; Romina Zarbl; Mike Florin; Pia Kuster; Gonzalo Saavedra; Susana Ramírez Valladolid; Friederike Hoffmann; Lukas Flatz; Sandra S Ring; Carsten Golletz; Torsten Pietsch; Sebastian Strieth; Peter Brossart; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

10.  RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Authors:  Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai
Journal:  J Neurooncol       Date:  2018-10-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.